Cargando…

512. Kinetics of SARS-CoV-2 IgG responses among hospitalized patients with COVID-19

BACKGROUND: The kinetics of antibody responses to SARS-CoV-2 infection are not fully understood. We analyzed IgG responses to the SARS-CoV-2 Spike protein receptor binding domain (RBD) in COVID-19 patients admitted to VA Greater Los Angeles (VAGLA) and correlated with clinical outcomes. METHODS: Ser...

Descripción completa

Detalles Bibliográficos
Autores principales: Beenhouwer, David O, Chintalacharuvu, Koteswara, Winnett, Alexander, Goldin, Evan, Bhattacharya, Debika, Graber, Christopher J, Goetz, Matthew B, Fulcher, Jennifer A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777288/
http://dx.doi.org/10.1093/ofid/ofaa439.706
_version_ 1783630867686490112
author Beenhouwer, David O
Chintalacharuvu, Koteswara
Winnett, Alexander
Goldin, Evan
Bhattacharya, Debika
Graber, Christopher J
Goetz, Matthew B
Fulcher, Jennifer A
author_facet Beenhouwer, David O
Chintalacharuvu, Koteswara
Winnett, Alexander
Goldin, Evan
Bhattacharya, Debika
Graber, Christopher J
Goetz, Matthew B
Fulcher, Jennifer A
author_sort Beenhouwer, David O
collection PubMed
description BACKGROUND: The kinetics of antibody responses to SARS-CoV-2 infection are not fully understood. We analyzed IgG responses to the SARS-CoV-2 Spike protein receptor binding domain (RBD) in COVID-19 patients admitted to VA Greater Los Angeles (VAGLA) and correlated with clinical outcomes. METHODS: Serially admitted patients from March 20-May 10, 2020 with at least one available residual serum specimen were included in this analysis. Serum samples selected for analysis included first, last, and intermediaries spaced ≥ 5 days apart, as available. Anti-RBD IgG was detected with an enzyme immunoassay (EIA) using recombinant RBD protein. Serum from an uninfected individual collected April 2019 was used as control. The average optical density of the control in triplicate plus 3 standard deviations was considered the threshold positive/negative value. The highest dilution above the threshold value was considered the IgG titer. Clinical groups were defined as asymptomatic, moderate/severe (no ICU) or critical (mechanical ventilation, cytokine storm and/or death). RESULTS: Of the 43 consecutive patients admitted to VAGLA with COVID-19 in this analysis, 40 developed detectable RBD IgG responses with maximum inverse titers (MIT) ranging 100-819,200, geometric mean 12,152. Five patients remained asymptomatic but had positive EIAs with median MIT 3200 (IQR 800–3200). Twenty-five had moderate-severe illness with median MIT 25600 (IQR 6400–102400). Ten patients with critical disease had median MIT 38400 (IQR 8800–51200). The median time to positive IgG was 10 days for asymptomatic (IQR 10,10), 4 days for moderate-severe (IQR 3,15), and 7 days for critical (IQR 3.5,14.5). The figure depicts RBD IgG titers over time after onset of symptoms. Asymptomatic patients had a more gradual rate of increase and lower peak titers, while critical patients had the fastest rate of rise and the highest peak titers. Of the 21 patients with samples > 30 days after symptom onset (range 31–67 days), there was no evidence for decrease in anti-RBD IgG. Kinetics of IgG to SARS-CoV-2 receptor binding domain by clinical severity CONCLUSION: Following infection with SARS-CoV-2, disease severity correlates with both the rate of increase and peak in antibody titers. Anti-RBD IgG titers did not decrease over the observation period. [Image: see text] DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-7777288
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77772882021-01-07 512. Kinetics of SARS-CoV-2 IgG responses among hospitalized patients with COVID-19 Beenhouwer, David O Chintalacharuvu, Koteswara Winnett, Alexander Goldin, Evan Bhattacharya, Debika Graber, Christopher J Goetz, Matthew B Fulcher, Jennifer A Open Forum Infect Dis Poster Abstracts BACKGROUND: The kinetics of antibody responses to SARS-CoV-2 infection are not fully understood. We analyzed IgG responses to the SARS-CoV-2 Spike protein receptor binding domain (RBD) in COVID-19 patients admitted to VA Greater Los Angeles (VAGLA) and correlated with clinical outcomes. METHODS: Serially admitted patients from March 20-May 10, 2020 with at least one available residual serum specimen were included in this analysis. Serum samples selected for analysis included first, last, and intermediaries spaced ≥ 5 days apart, as available. Anti-RBD IgG was detected with an enzyme immunoassay (EIA) using recombinant RBD protein. Serum from an uninfected individual collected April 2019 was used as control. The average optical density of the control in triplicate plus 3 standard deviations was considered the threshold positive/negative value. The highest dilution above the threshold value was considered the IgG titer. Clinical groups were defined as asymptomatic, moderate/severe (no ICU) or critical (mechanical ventilation, cytokine storm and/or death). RESULTS: Of the 43 consecutive patients admitted to VAGLA with COVID-19 in this analysis, 40 developed detectable RBD IgG responses with maximum inverse titers (MIT) ranging 100-819,200, geometric mean 12,152. Five patients remained asymptomatic but had positive EIAs with median MIT 3200 (IQR 800–3200). Twenty-five had moderate-severe illness with median MIT 25600 (IQR 6400–102400). Ten patients with critical disease had median MIT 38400 (IQR 8800–51200). The median time to positive IgG was 10 days for asymptomatic (IQR 10,10), 4 days for moderate-severe (IQR 3,15), and 7 days for critical (IQR 3.5,14.5). The figure depicts RBD IgG titers over time after onset of symptoms. Asymptomatic patients had a more gradual rate of increase and lower peak titers, while critical patients had the fastest rate of rise and the highest peak titers. Of the 21 patients with samples > 30 days after symptom onset (range 31–67 days), there was no evidence for decrease in anti-RBD IgG. Kinetics of IgG to SARS-CoV-2 receptor binding domain by clinical severity CONCLUSION: Following infection with SARS-CoV-2, disease severity correlates with both the rate of increase and peak in antibody titers. Anti-RBD IgG titers did not decrease over the observation period. [Image: see text] DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7777288/ http://dx.doi.org/10.1093/ofid/ofaa439.706 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Beenhouwer, David O
Chintalacharuvu, Koteswara
Winnett, Alexander
Goldin, Evan
Bhattacharya, Debika
Graber, Christopher J
Goetz, Matthew B
Fulcher, Jennifer A
512. Kinetics of SARS-CoV-2 IgG responses among hospitalized patients with COVID-19
title 512. Kinetics of SARS-CoV-2 IgG responses among hospitalized patients with COVID-19
title_full 512. Kinetics of SARS-CoV-2 IgG responses among hospitalized patients with COVID-19
title_fullStr 512. Kinetics of SARS-CoV-2 IgG responses among hospitalized patients with COVID-19
title_full_unstemmed 512. Kinetics of SARS-CoV-2 IgG responses among hospitalized patients with COVID-19
title_short 512. Kinetics of SARS-CoV-2 IgG responses among hospitalized patients with COVID-19
title_sort 512. kinetics of sars-cov-2 igg responses among hospitalized patients with covid-19
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777288/
http://dx.doi.org/10.1093/ofid/ofaa439.706
work_keys_str_mv AT beenhouwerdavido 512kineticsofsarscov2iggresponsesamonghospitalizedpatientswithcovid19
AT chintalacharuvukoteswara 512kineticsofsarscov2iggresponsesamonghospitalizedpatientswithcovid19
AT winnettalexander 512kineticsofsarscov2iggresponsesamonghospitalizedpatientswithcovid19
AT goldinevan 512kineticsofsarscov2iggresponsesamonghospitalizedpatientswithcovid19
AT bhattacharyadebika 512kineticsofsarscov2iggresponsesamonghospitalizedpatientswithcovid19
AT graberchristopherj 512kineticsofsarscov2iggresponsesamonghospitalizedpatientswithcovid19
AT goetzmatthewb 512kineticsofsarscov2iggresponsesamonghospitalizedpatientswithcovid19
AT fulcherjennifera 512kineticsofsarscov2iggresponsesamonghospitalizedpatientswithcovid19